AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36274582 — intervention group
Group type: COMPARATOR
Intervention: Tape on the dorsum of the hand (T1)
Number of subjects: 11
Study 36274582 — intervention group
Group type: COMPARATOR
Intervention: No tape (NT)
Number of subjects: 11
Study 32770665 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic immediate‐release tofacitinib tablet (5 mg)
Number of subjects: 52
Study 32770665 — intervention group
Group type: COMPARATOR
Intervention: Brand‐named immediate‐release tofacitinib tablet (5 mg)
Number of subjects: 52
Study 32770665 — intervention group
Group type: COMPARATOR
Intervention: High-fat food effect
Number of subjects: 52
Study 35763413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3256
Study 32173638 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil and dexmedetomidine
Number of subjects: 160
Study 32173638 — intervention group
Group type: COMPARATOR
Intervention: sufentanil and normal saline
Number of subjects: 160
Study 35606022 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular, low-dose, sustained-release morphine
Number of subjects: 22
Study 34819515 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT combined with conventional physical therapy (ICT-C)
Number of subjects: 20
Study 34819515 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy and gait training (CPT-G)
Number of subjects: 20
Study 35135524 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and service provision for volunteers
Number of subjects: 107
Study 35135524 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia attitude and knowledge
Number of subjects: 107
Study 33724600 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week adaptive working memory training (WMT)
Number of subjects: 59
Study 33724600 — intervention group
Group type: COMPARATOR
Intervention: 8-week nonadaptive intervention (active controls)
Number of subjects: 59
Study 36164102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafasitamab (12 mg/kg IV on days 1, 8, 15, and 22 of a 28-day cycle for cycles 1-3, then days 1 and 15 for cycles 4-12) plus Lenalidomide (20 mg PO QD, days 1-21/cycle for 12 cycles) and Rituximab (375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1, then day 1 of cycles 2-5)
Number of subjects: 588
Study 36164102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafasitamab plus Lenalidomide and Rituximab
Number of subjects: 588
Study 36164102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution IV) plus Lenalidomide and Rituximab
Number of subjects: 588
Study 34047672 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 in-person hypnosis contacts
Number of subjects: 90
Study 34047672 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 in-person hypnosis contacts
Number of subjects: 90
Study 34047672 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 phone hypnosis contacts
Number of subjects: 90
Study 34047672 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 phone hypnosis contacts
Number of subjects: 90
Study 33393645 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP (B-type natriuretic peptide) via intravenous infusion, 2 µg/kg bolus followed by infusion at 0.01, 0.02, and 0.03 µg/kg/min for 1.5 hours
Number of subjects: 40
Study 33393645 — intervention group
Group type: COMPARATOR
Intervention: Nebulized salbutamol (control group)
Number of subjects: 40
Study 33393645 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP (B-type natriuretic peptide)
Number of subjects: 40
Study 33878621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusions (6 infusions over 2 weeks)
Number of subjects: 83
Study 33878621 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning prediction models
Number of subjects: 83
Study 32957482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (two atmospheres of 100% oxygen)
Number of subjects: 56
Study 32957482 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (simulation of increased pressure in a chamber with normal air)
Number of subjects: 56
Study 36113061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided peripheral intravenous catheters (PIVC)
Number of subjects: 257
Study 36113061 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of catheter in vein >2.75 cm
Number of subjects: 257
Study 36113061 — intervention group
Group type: EXPERIMENTAL
Intervention: First stick success
Number of subjects: 257
Study 36113061 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth of vein >1.2 cm
Number of subjects: 257
Study 36113061 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVC placement in right extremity
Number of subjects: 257
Study 32102610 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery Training (MIT) plus conventional rehabilitation therapy (CRT)
Number of subjects: 34
Study 32102610 — intervention group
Group type: COMPARATOR
Intervention: Control group (only received CRT)
Number of subjects: 34
Study 34871100 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe feeding
Number of subjects: 75
Study 34871100 — intervention group
Group type: COMPARATOR
Intervention: Paladai feeding
Number of subjects: 75
Study 32072340 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar dissection preferred (MDP)
Number of subjects: 103
Study 32072340 — intervention group
Group type: COMPARATOR
Intervention: Blunt dissection preferred (BDP)
Number of subjects: 103
Study 32072340 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 35257498 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of therapy
Number of subjects: 49
Study 33287744 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examinations for 3 years + whole-body imaging with CT or FDG-PET/CT and laboratory tests including S100B protein and LDH
Number of subjects: 1300
Study 33287744 — intervention group
Group type: COMPARATOR
Intervention: Clinical examinations for 3 years
Number of subjects: 1300
Study 35338036 — intervention group
Group type: EXPERIMENTAL
Intervention: Early lengthening exercises (at day 1 of rehabilitation)
Number of subjects: 90
Study 35338036 — intervention group
Group type: COMPARATOR
Intervention: Delayed lengthening exercises (after being able to run at 70% of maximal speed)
Number of subjects: 90
Study 35338036 — intervention group
Group type: EXPERIMENTAL
Intervention: Early lengthening group
Number of subjects: 90
Study 35338036 — intervention group
Group type: COMPARATOR
Intervention: Reinjury rates within 2 months
Number of subjects: 90
Study 35338036 — intervention group
Group type: COMPARATOR
Intervention: Reinjury rates from 2 to 6 months
Number of subjects: 90
Study 35338036 — intervention group
Group type: COMPARATOR
Intervention: Reinjury rates from 6 to 12 months
Number of subjects: 90
Study 33049392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (27.5 μg) 2 sprays once daily for 1 week, followed by as-needed use for 5 weeks (FF-as-needed)
Number of subjects: 108
Study 33049392 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate nasal spray (27.5 μg) 2 sprays once daily for 6 weeks (FF-regular)
Number of subjects: 108
Study 33049392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FF-as-needed and FF-regular)
Number of subjects: 108
Study 33049392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FF-as-needed)
Number of subjects: 108
Study 32889771 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% H2 O2 gel
Number of subjects: 72
Study 32889771 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% H2 O2 + 3% TMP + 0.1% NaF
Number of subjects: 72
Study 32889771 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% H2 O2 + 0.3% TMP + 0.05% NaF
Number of subjects: 72
Study 32889771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice
Number of subjects: 72
Study 32889771 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 72
Study 35192640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Problem-Based Pedagogy (PBP)
Number of subjects: 660
Study 35192640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure Problem-Based Pedagogy (PBP)
Number of subjects: 660
Study 35192640 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 660
Study 35192640 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months
Number of subjects: 660
Study 35192640 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months
Number of subjects: 660
Study 33189909 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gelatin-thrombin matrix sealant (TGTMS)
Number of subjects: 103
Study 33189909 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TGTMS)
Number of subjects: 103
Study 33189909 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with active bleeding requiring TGTMS (I group)
Number of subjects: 103
Study 35179593 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 0
Study 35179593 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Alone
Number of subjects: 0
Study 35656688 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 102
Study 35656688 — intervention group
Group type: COMPARATOR
Intervention: Strip crowns
Number of subjects: 102
Study 34647858 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 82
Study 34647858 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Therapy (PMRT)
Number of subjects: 82
Study 34647858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 34551211 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT (Volumetric Modulated Arc Therapy)
Number of subjects: 21
Study 34551211 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT (Three-Dimensional Conformal Radiation Therapy)
Number of subjects: 21
Study 34310904 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen receptor inhibitors (apalutamide, enzalutamide, or daralutamide)
Number of subjects: 4117
Study 34310904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4117
Study 32503517 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose yoga (LD), 60 min per week
Number of subjects: 90
Study 32503517 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose yoga (MD), 150 min per week
Number of subjects: 90
Study 32503517 — intervention group
Group type: COMPARATOR
Intervention: Stretch-and-tone control group (STC)
Number of subjects: 90
Study 36411058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Number of subjects: 157
Study 36411058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 36411058 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 157
Study 33044394 — intervention group
Group type: EXPERIMENTAL
Intervention: EMONO (1-hour administration of equimolar mixture of oxygen and nitrous oxide)
Number of subjects: 240
Study 33044394 — intervention group
Group type: COMPARATOR
Intervention: Placebo (medical air)
Number of subjects: 240
Study 35590386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase 0.25 mg/kg
Number of subjects: 0
Study 35590386 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (no thrombolysis)
Number of subjects: 0
Study 33079379 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 563
Study 33079379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 32199541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT) + Work Therapy (WT)
Number of subjects: 48
Study 32199541 — intervention group
Group type: COMPARATOR
Intervention: Work Therapy (WT)
Number of subjects: 48
Study 32199541 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 48
Study 36156571 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic Constraint-Induced Movement Therapy (CCIMT)
Number of subjects: 40
Study 36156571 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy (MCIMT)
Number of subjects: 40
Study 36156571 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 33141791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham Wi‐Fi on
Number of subjects: 83
Study 33141791 — intervention group
Group type: COMPARATOR
Intervention: Sham Wi‐Fi off
Number of subjects: 83
Study 32088365 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Psychology (PP) intervention, 8-session weekly phone-delivered group format
Number of subjects: 29
Study 91213894 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g wheat bran (WB)
Number of subjects: 34
Study 91213894 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g wheat bran (WB)
Number of subjects: 34
Study 91213894 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g mixed vegetable fiber (VF)
Number of subjects: 34
Study 91213894 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g mixed vegetable fiber (VF)
Number of subjects: 34
Study 91213894 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g sugar-beet fiber (SBF)
Number of subjects: 34
Study 91213894 — intervention group
Group type: COMPARATOR
Intervention: Fiber-free diet
Number of subjects: 34
Study 35241345 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin (0.3–1 g × kg−1 × day−1)
Number of subjects: 3
Study 35241345 — intervention group
Group type: COMPARATOR
Intervention: Placebo liquid
Number of subjects: 3
Study 35241345 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Number of subjects: 3
Study 32044339 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation manipulation (prompting to focus on positive outcomes of winning)
Number of subjects: 98
Study 32044339 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition (control group)
Number of subjects: 98
Study 34397085 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask worn by confederate
Number of subjects: 2722
Study 34184295 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg orally for 24 weeks)
Number of subjects: 92
Study 34184295 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24 weeks)
Number of subjects: 92
Study 34184295 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg orally for 24 weeks) in nondiabetic patients
Number of subjects: 92
Study 34184295 — intervention group
Group type: COMPARATOR
Intervention: Placebo in diabetic patients
Number of subjects: 92
Study 36285795 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d)
Number of subjects: 1025
Study 36285795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1025
Study 36285795 — intervention group
Group type: EXPERIMENTAL
Intervention: n−3 fatty acids (1 g/d)
Number of subjects: 1025
Study 32576151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine by continuous intravenous administration
Number of subjects: 40
Study 32576151 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 40
Study 34954348 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared sauna
Number of subjects: 10
Study 34954348 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 10
Study 34954348 — intervention group
Group type: COMPARATOR
Intervention: Control (resting)
Number of subjects: 10
Study 36198051 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine umbilical cord MSCs
Number of subjects: 80
Study 33526970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum-GMNL6
Number of subjects: 0
Study 32760144 — intervention group
Group type: EXPERIMENTAL
Intervention: Aussie-FIT intervention (12 weekly 90-min sessions)
Number of subjects: 130
Study 32760144 — intervention group
Group type: EXPERIMENTAL
Intervention: Aussie-FIT intervention
Number of subjects: 130
Study 32760144 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 35417878 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone phonophoresis (10%) combined with static progressive stretching and home exercise program
Number of subjects: 29
Study 35417878 — intervention group
Group type: COMPARATOR
Intervention: Static progressive stretching and home exercise program
Number of subjects: 29
Study 35436823 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of low-dose hydrocortisone therapy
Number of subjects: 120
Study 35436823 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 120
Study 34510642 — intervention group
Group type: COMPARATOR
Intervention: Frail patients compared to robust patients
Number of subjects: 541
Study 34510642 — intervention group
Group type: COMPARATOR
Intervention: Prefrail patients compared to robust patients
Number of subjects: 541
Study 32166624 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amitriptyline (25 mg once daily before bedtime)
Number of subjects: 60
Study 32166624 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment with pantoprazole (40 mg once daily)
Number of subjects: 60
Study 35810012 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Number of subjects: 28
Study 35810012 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 33578661 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive outreach educational intervention (oral health education in two one-hour sessions)
Number of subjects: 66
Study 33578661 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 66
Study 32091226 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-led Body Project
Number of subjects: 680
Study 32091226 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led Body Project
Number of subjects: 680
Study 32091226 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based eBody Project
Number of subjects: 680
Study 32091226 — intervention group
Group type: COMPARATOR
Intervention: Educational video control
Number of subjects: 680
Study 35247906 — intervention group
Group type: EXPERIMENTAL
Intervention: Famitinib (20 mg orally on days 1-28), Camrelizumab (200 mg intravenously on days 1 and 15), Nab-paclitaxel (100 mg/m2 intravenously on days 1, 8, and 15 in 4-week cycles)
Number of subjects: 48
Study 35247906 — intervention group
Group type: EXPERIMENTAL
Intervention: Famitinib, Camrelizumab, and Nab-paclitaxel combination
Number of subjects: 48
Study 32529630 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug intervention clinical trials (various drugs including molecular target drugs)
Number of subjects: 200
Study 32529630 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 3, randomized, blinded, for-profit-company supported/sponsored, multi-center trials
Number of subjects: 200
Study 32529630 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials of newly developed molecular target drugs (e.g., EGFR-TKIs, ALK inhibitors, immune checkpoint inhibitors)
Number of subjects: 200
Study 34601588 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended information about the CT examination including visualization of individual coronary calcium score images.
Number of subjects: 92
Study 34601588 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no extended information or examination result).
Number of subjects: 92
Study 34601588 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended information about the CT examination.
Number of subjects: 92
Study 34601588 — intervention group
Group type: COMPARATOR
Intervention: Standard care.
Number of subjects: 92
Study 32863075 — intervention group
Group type: EXPERIMENTAL
Intervention: Poster intervention
Number of subjects: 105
Study 32863075 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 105
Study 32201919 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon juice
Number of subjects: 0
Study 32201919 — intervention group
Group type: COMPARATOR
Intervention: Black tea
Number of subjects: 0
Study 32201919 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 32201919 — intervention group
Group type: COMPARATOR
Intervention: None of the tested beverages
Number of subjects: 0
Study 36480397 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 241
Study 36480397 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced drinking (1-3 WHO drinking risk levels without abstinence)
Number of subjects: 241
Study 36480397 — intervention group
Group type: COMPARATOR
Intervention: Nonreduced drinking (maintained or increased drinking risk level)
Number of subjects: 241
Study 36480397 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 241
Study 36480397 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and functional outcomes
Number of subjects: 241
Study 34315697 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise-hierarchical pooled analysis method
Number of subjects: 0
Study 32619524 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous (IV) thiamine
Number of subjects: 60
Study 32619524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35459114 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity hardstyle kettlebell training
Number of subjects: 32
Study 33875487 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1RA
Number of subjects: 16690
Study 33875487 — intervention group
Group type: COMPARATOR
Intervention: DPP-4I
Number of subjects: 16690
Study 35435039 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (4 g twice daily from 2 days before melphalan until day +28) along with standard supportive care
Number of subjects: 40
Study 35435039 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard supportive care)
Number of subjects: 40
Study 36213563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral implant restoration
Number of subjects: 118
Study 36213563 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentition restoration
Number of subjects: 118
Study 34173380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-driven HIV screening offered to key populations in EDs
Number of subjects: 218
Study 34173380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-driven HIV screening
Number of subjects: 218
Study 32286659 — intervention group
Group type: COMPARATOR
Intervention: Tailored BBTI
Number of subjects: 92
Study 32286659 — intervention group
Group type: COMPARATOR
Intervention: Standard BBTI
Number of subjects: 92